Antidepressant continuation and adherence in pregnancy, and risk of antenatal hospitalization for unipolar major depressive and/or anxiety disorders.

[1]  N. Trinh,et al.  Antidepressant and mental health care utilization in pregnant women with depression and/or anxiety: An interrupted time-series analysis. , 2022, Journal of affective disorders.

[2]  E. Agerbo,et al.  Antidepressant discontinuation before or during pregnancy and risk of psychiatric emergency in Denmark: A population-based propensity score–matched cohort study , 2022, PLoS medicine.

[3]  H. Bayrampour,et al.  The Risk of Relapse of Depression During Pregnancy After Discontinuation of Antidepressants: A Systematic Review and Meta-Analysis. , 2020, The Journal of clinical psychiatry.

[4]  J. Stingl,et al.  The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis , 2020, Expert opinion on drug metabolism & toxicology.

[5]  Xiuyang Li,et al.  Propensity score analysis for time-dependent exposure , 2020, Annals of translational medicine.

[6]  V. Bergink,et al.  The international prevalence of antidepressant use before, during, and after pregnancy: A systematic review and meta-analysis of timing, type of prescriptions and geographical variability. , 2019, Journal of affective disorders.

[7]  C. Chambers,et al.  Impact of antidepressant use, discontinuation, and dosage modification on maternal depression during pregnancy , 2019, European Neuropsychopharmacology.

[8]  S. Patten,et al.  Adherence to and Persistence with Antidepressant Medication during Pregnancy: Does It Differ by the Class of Antidepressant Medication Prescribed? , 2018, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[9]  P. Austin.  Assessing the performance of the generalized propensity score for estimating the effect of quantitative or continuous exposures on binary outcomes , 2018, Statistics in medicine.

[10]  C. Giaquinto,et al.  Use of antidepressant medication in pregnancy and adverse neonatal outcomes: A population‐based investigation , 2017, Pharmacoepidemiology and drug safety.

[11]  Patrik Magnusson,et al.  Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. , 2017, The lancet. Psychiatry.

[12]  C. Dennis,et al.  The prevalence of antenatal and postnatal co-morbid anxiety and depression: a meta-analysis , 2017, Psychological Medicine.

[13]  G. Corrao,et al.  The lag-time approach improved drug-outcome association estimates in presence of protopathic bias. , 2016, Journal of clinical epidemiology.

[14]  S. Hernández-Díaz,et al.  Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data , 2015, Pharmacoepidemiology and drug safety.

[15]  O. Spigset,et al.  PATTERNS AND FACTORS ASSOCIATED WITH LOW ADHERENCE TO PSYCHOTROPIC MEDICATIONS DURING PREGNANCY—A CROSS‐SECTIONAL, MULTINATIONAL WEB‐BASED STUDY , 2015, Depression and anxiety.

[16]  L. Altshuler,et al.  Acute and long-term behavioral outcome of infants and children exposed in utero to either maternal depression or antidepressants: a review of the literature. , 2014, The Journal of clinical psychiatry.

[17]  Peter C Austin,et al.  A comparison of 12 algorithms for matching on the propensity score , 2013, Statistics in medicine.

[18]  Megan V. Smith,et al.  Does Antidepressant Use Attenuate the Risk of a Major Depressive Episode in Pregnancy? , 2011, Epidemiology.

[19]  I. Petersen,et al.  Pregnancy as a major determinant for discontinuation of antidepressants: an analysis of data from The Health Improvement Network. , 2011, The Journal of clinical psychiatry.

[20]  B. Martin,et al.  Contrasting Measures of Adherence with Simple Drug Use, Medication Switching, and Therapeutic Duplication , 2009, The Annals of pharmacotherapy.

[21]  J. LeLorier,et al.  Application of lag‐time into exposure definitions to control for protopathic bias , 2007, Pharmacoepidemiology and drug safety.

[22]  B. Vandermeer,et al.  Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis , 2006, BMJ : British Medical Journal.

[23]  O. Spigset,et al.  Safety of Psychotropic Drugs in Pregnancy and Breastfeeding , 2016 .